Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when WST files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Related Party (new) — The agreements are with Daikyo, in which West holds a 49% ownership stake, making this a related-party transaction that warrants scrutiny of terms and governance.
West Pharmaceutical renews 10-year technology and distribution pact with 49%-owned Daikyo
Filed July 14, 2026 · Period ending July 14, 2026 · ~1 min read
Key Changes
-
high
West renewed technology-sharing, crosslicensing, and distribution agreements with Daikyo Seiko, in which West holds a 49% ownership stake, for another 10 years through 2036.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
high
West receives exclusive license to Daikyo's pharmaceutical packaging technology outside Japan and exclusive global distribution rights for Daikyo products; Daikyo gets non-exclusive license to West's technology and non-exclusive distribution rights in Japan.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
medium
Agreements are largely royalty-free except for certain patents and technical information; either party can terminate upon change of control or mutual consent.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
Summary
West Pharmaceutical renewed three interconnected agreements with Daikyo Seiko, a Japanese pharmaceutical packaging company in which West holds a 49% ownership interest. The 10-year pact extends West's exclusive access to Daikyo's technology outside Japan and its exclusive global distribution rights for Daikyo products, while granting Daikyo non-exclusive rights to West's technology and products within Japan. The arrangement is substantially similar to the prior 2017 agreements and is largely royalty-free.
The related-party nature of the transaction raises governance questions about whether the terms reflect arm's-length negotiation, particularly given the asymmetry in exclusivity (West receives exclusive licenses and distribution rights globally outside Japan, while Daikyo's rights are non-exclusive). The 49% ownership stake means West lacks control but has significant influence over Daikyo, and the agreements effectively lock in the commercial relationship through 2036. Investors should watch for disclosure of any board review process or fairness opinion, and monitor whether the partnership continues to deliver competitive advantages in pharmaceutical packaging markets.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
West Pharmaceutical Services, Inc. (the "Company") and Daikyo Seiko, Ltd. ("Daikyo") have entered into an Amended and Restated Technology Exchange and Crosslicense Agreement (the “Crosslicense Agreement”) as well as two Distributorship Agreements (the “Distributorship Agreements”) effective July 14, 2026 (the “Agreements”). The Company maintains a 49% ownership interest in Daikyo.
West renewed three key agreements with Daikyo Seiko, a company in which West holds a 49% ownership interest. The agreements cover technology sharing, crosslicensing, and distribution rights for pharmaceutical packaging components. The terms are substantially similar to the prior 2017 agreements.
Added in current filing · verify on EDGAR →
Under the Crosslicense Agreement, each party has agreed to share with the other its know-how relating to, and to cooperate in the joint development of, closures, vials, cartridges, syringes, medical device components and similar products used in connection with the packaging, delivery, administration or dispensing of pharmaceutical products. The Crosslicense Agreement permits each party to license the other’s know-how, patents and trademarks in the manufacture, use and sale of those products. Daikyo’s license from West is non-exclusive and West’s license from Daikyo is exclusive outside of Japan subject to certain limited exceptions. The Crosslicense Agreement is royalty-free except for a fixed royalty rate that is generally applicable to the licensing of certain patents and non-patented technical information.
The Crosslicense Agreement enables both parties to share know-how and jointly develop pharmaceutical packaging products. West receives an exclusive license to Daikyo's technology outside Japan, while Daikyo receives a non-exclusive license to West's technology. The arrangement is largely royalty-free except for certain patents and technical information.
Added in current filing · verify on EDGAR →
One Distributorship Agreement authorizes the Company as the exclusive distributor of Daikyo products in all countries other than Japan, subject to certain limited exceptions. The other Distributorship Agreement authorizes Daikyo as a non-exclusive distributor of Company products in Japan.
West secured exclusive distribution rights for Daikyo products globally outside Japan, while Daikyo received non-exclusive distribution rights for West products within Japan. This structure allows West to control Daikyo's international market access while maintaining flexibility in Japan.
Added in current filing · verify on EDGAR →
Each of the Agreements has a 10-year term. Each Agreement may be terminated before its respective term expires under certain circumstances, including, but not limited to, mutual written consent or in the event of a change in control of either party.
All three agreements run for 10 years and include termination provisions for mutual consent or change of control events. This provides long-term stability for the partnership while allowing exit options if ownership structures change at either company.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 16, 2026 · How we verify